Malik Fady Ibraham 4

What Happened

• Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised options to acquire 3,500 shares and sold 3,500 shares in an open-market transaction on June 9, 2026.
• He exercised 3,500 option-based shares at a $7.80 strike (cost = $27,300) and sold 3,500 shares at $67.98 each (proceeds = $237,930). The filing also shows a derivative conversion/disposition of 3,500 units at $0—consistent with options being converted/surrendered as part of the exercise.
• This is effectively a cashless exercise followed by an immediate sale (liquidity event), rather than a net purchase indicating added ownership.

Key Details

• Transaction date: 2026-06-09.
• Exercise: 3,500 shares @ $7.80 = $27,300 total; Sale: 3,500 shares @ $67.98 = $237,930 total.
• Filing indicates a derivative conversion/disposition of 3,500 units at $0 consideration (typical when options are converted into shares upon exercise).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: reported on the same date (no late filing indicated).
• No 10b5-1 plan, tax-withholding, or other footnotes were provided in the supplied data.

Context

• For retail investors: this pattern—exercising options and immediately selling the resulting shares—is a common way for insiders to capture gains or cover option costs and tax obligations and does not necessarily indicate a change in view about the company.
• Because this was a sale rather than an outright purchase, it is less informative as a bullish signal about future company prospects.